From BioHealth Investor
Shares of Dynavax Technologies Corp (DVAX) jumped more than 30% on Wednesday after the company announced that its Hepatitis B phase III clinical study showed positive results. The announcement came following market close on Tuesday.
The study showed a statistically significant advantage of Dynavax’s HEPLISAV HEP B vaccine when compared to the conventional vaccine, Engerix-B, developed by GlaxoSmithKline (GSK).
What is of primary importance is the fact that HEPLISAV outperformed Engerix-B in older subjects, a population who has historically proven more difficult to immunize.
It was able to provide over 98% protection in this older population after only two doses.
Further trials of HEPLISAV are planned to take place in Canada and Europe to investigate multiple dosing regimens and the effects of the vaccine in differing age populations. Dynavax expects these trials to conclude in 2008.
Shares of Dynavax closed at $9.79 after establishing a new intraday 52-week high.
http://www.biohealthinvestor.com/
ALERT: Take This Retirement Quiz Now (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
